China SXT Pharmaceuticals, Inc.
SXTC
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces. Its product lineup includes directly-oral, after-soaking-oral, fine, and regular TCMP formats, which are distributed under brands such as Suxuantang, Hui Chun Tang, and Tong Ren Tang. The company serves a range of customers in China, including hospitals, chain pharmacies, pharmaceutical distributors, and commercial pharmaceutical companies, positioning it within the domestic traditional medicine supply chain. Based in Taizhou, Jiangsu, China, China SXT Pharmaceuticals, Inc. operates in a specialized segment of the healthcare market centered on traditional Chinese medicine products.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▼ -34.6% YoY
Net Income (TTM)
-$6M
▼ -87.8% YoY
Op. Margin
-625.89%
▼ -471.9pp YoY
ROIC
-23.82%
▼ -11.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▼ -124.4% YoY
Op. Cash Flow (TTM)
-$4M
▼ -71.3% YoY
Net Debt
-$27M
Net Cash Position
Cash & Equiv.
$28M
3Y CAGR: -16.7%
Continue Research
Peers
Drug Manufacturers - Specialty & Generic · Pick stocks to compare with SXTC
China SXT Pharmaceuticals (SXTC) in four numbers
Questions about China SXT Pharmaceuticals
Is China SXT Pharmaceuticals (SXTC) overvalued?
At $2.60, China SXT Pharmaceuticals' price is 100% below the $1,849.84 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is China SXT Pharmaceuticals' fair value?
Intrinsiqq's calculator puts China SXT Pharmaceuticals' fair value at $1,849.84 a share. It grows revenue per share 0% a year for 5 years, applies an exit P/S of 3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $1,387.38. Every input can be changed on the Intrinsic Value tab.
Is China SXT Pharmaceuticals a high-quality business?
China SXT Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from company filings. Its best check is net debt at -$27M, and its weakest is return on capital at -23.8%. The Quality tab shows every check against its target.
Does China SXT Pharmaceuticals (SXTC) pay a dividend?
No. China SXT Pharmaceuticals (SXTC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SXTC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.